Renalytix Plc
RNLXY
$1.24
-$0.13-9.19%
OTC PK
| 12/31/2025 | 09/30/2025 | 12/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 800.00K | 800.00K | 778.00K | 535.00K | 709.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 800.00K | 800.00K | 778.00K | 535.00K | 709.00K |
| Cost of Revenue | 400.00K | 400.00K | 378.00K | 601.00K | 480.00K |
| Gross Profit | 400.00K | 400.00K | 400.00K | -66.00K | 229.00K |
| SG&A Expenses | 3.60M | 3.60M | 4.23M | 3.88M | 5.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.30M | 4.30M | 3.99M | 6.67M | 9.04M |
| Operating Income | -3.50M | -3.50M | -3.21M | -6.14M | -8.34M |
| Income Before Tax | -4.05M | -4.05M | -3.87M | -7.74M | -8.48M |
| Income Tax Expenses | -- | -- | -2.00K | -- | 4.00K |
| Earnings from Continuing Operations | -4.05M | -4.05M | -3.87M | -7.74M | -8.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.05M | -4.05M | -3.87M | -7.74M | -8.49M |
| EBIT | -3.50M | -3.50M | -3.21M | -6.14M | -8.34M |
| EBITDA | -- | -- | -3.15M | -6.07M | -8.23M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.08 | -0.09 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.04 | -0.05 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.08 | -0.09 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 382.51M | 382.51M | 213.36M | 97.66M | 97.27M |
| Average Diluted Shares Outstanding | 382.51M | 382.51M | 213.36M | 97.66M | 97.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |